Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.9433
- Book/Share 32.6431
- PB 5.7718
- Debt/Equity 0.0806
- CurrentRatio 1.0736
- ROIC 0.1293
- MktCap 453935290168.0
- FreeCF/Share 7.8498
- PFCF 23.8111
- PE 18.2162
- Debt/Assets 0.0331
- DivYield 0.027
- ROE 0.3269
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Daiwa Securities | Neutral | Outperform | -- | $203 | Oct. 20, 2025 |
| Upgrade | JNJ | Wells Fargo | Equal Weight | Overweight | -- | $212 | Oct. 3, 2025 |
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
Published: October 10, 2025 by: Reuters
Sentiment: Positive
Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter.
Read More
Johnson & Johnson in Talks to Buy Protagonist Therapeutics
Published: October 10, 2025 by: WSJ
Sentiment: Positive
The two companies are already codeveloping a treatment for ulcerative colitis.
Read More
Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Goldman Sachs expects another quarter of outperformance from J&J in Q3
Published: October 08, 2025 by: Proactive Investors
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ)'s strong year-to-date performance is likely to continue when the healthcare giant reports third quarter earnings on October 14, according to analysts at Goldman Sachs. The firm wrote in a note to clients that the stock's 31% gain this year, which is more than double the S&P 500's 14% rise, reflects “impressive execution across the Innovative Medicines segment,” which has driven sales and earnings estimates higher relative to peers.
Read More
Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Read More
Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
Published: October 06, 2025 by: MarketBeat
Sentiment: Neutral
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.
Read More
2 Dividend Stocks That Jim Cramer Wants Every Retiree to Own
Published: October 03, 2025 by: 24/7 Wall Street
Sentiment: Positive
Retirees and older individuals are among the biggest demographics who tune into Jim Cramer's Mad Money show.
Read More
Why JNJ Stock Defines Shareholder Supremacy In Healthcare
Published: September 30, 2025 by: Forbes
Sentiment: Positive
Over the past ten years, Johnson & Johnson (NYSE: JNJ) has delivered an impressive $157 Bil back to its investors through cash distributions via dividends and buybacks. This commitment to shareholder value has translated into exceptional market performance in 2025, with the stock delivering a remarkable 26% year-to-date return, significantly outpacing the broader healthcare sector and demonstrating the defensive strength that has made JNJ a cornerstone holding for income-focused investors.
Read More
3 Ultra-Safe Dividend Stocks to Buy Now, If You're Concerned About Volatility Ahead
Published: September 30, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors who find themselves awake at night thinking about their portfolios, fear not.
Read More
Johnson & Johnson (JNJ) Could Be a Great Choice
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Read More
Should You Invest in Johnson & Johnson (JNJ) Based on Bullish Wall Street Views?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J shares gain 17.7% in three months, adding $63B to its market cap. Technical and pipeline momentum fuel investor interest.
Read More
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.
Read More
J&J's experimental psoriasis drug shows promise against Bristol's treatment
Published: September 17, 2025 by: Reuters
Sentiment: Positive
Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.
Read More
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
Published: September 17, 2025 by: PRNewsWire
Sentiment: Neutral
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD study Robust findings continue to demonstrate the potential of icotrokinra to disrupt the treatment paradigm to set a new standard for treating patients with moderate-to-severe plaque psoriasis SPRING HOUSE, Pa. , Sept. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 …
Read More
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Published: September 12, 2025 by: Market Watch
Sentiment: Negative
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
Read More
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
Read More
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Johnson & Johnson (JNJ) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Joaquin Duato - CEO & Chairman John Reed - Executive Vice President of Innovative Medicine, R&D Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.
Read More
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Negative
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Johnson & Johnson: JNJ Stock To $250?
Published: September 09, 2025 by: Forbes
Sentiment: Positive
Johnson & Johnson stock (NYSE: JNJ) has delivered a remarkable 24% return in 2025 even as the S&P 500 healthcare index declined 0.2%. This raises an important question: Is this outperformance grounded in durable business fundamentals, or is it a temporary market anomaly?
Read More
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
Published: September 08, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100